Overview

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.